PNB Vesper achieve drug controller's nod to launch phase-II clinical trials for a coronavirus drug
Image Credit: shortpedia
PNB Vesper has secured the drug controller's nod to launch phase-II clinical trials for a potential coronavirus drug. The 15-year-old company has developed six new chemical entities and the latest one PNB001 will be tested for treating coronavirus patients. The molecule was initially developed for lung cancer, the company's promoter and chief executive P N Balaram told media. Firm's labs are located in Britain.